These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22969064)

  • 1. Embryo-fetal transfer of bevacizumab (Avastin) in the rat over the course of gestation and the impact of neonatal Fc receptor (FcRn) binding.
    Thorn M; Piche-Nicholas N; Stedman D; Davenport SW; Zhang N; Collinge M; Bowman CJ
    Birth Defects Res B Dev Reprod Toxicol; 2012 Oct; 95(5):363-75. PubMed ID: 22969064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placental transfer of (125)Iodinated humanized immunoglobulin G2Δa in the Sprague Dawley rat.
    Coder PS; Thomas JA; Stedman DB; Bowman CJ
    Reprod Toxicol; 2013 Jul; 38():37-46. PubMed ID: 23462583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Embryo-fetal distribution of a biopharmaceutical IgG2 during rat organogenesis.
    Bowman CJ; King LE; Stedman DB
    Reprod Toxicol; 2012 Aug; 34(1):66-72. PubMed ID: 22543284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placental transfer of Fc-containing biopharmaceuticals across species, an industry survey analysis.
    Bowman CJ; Breslin WJ; Connor AV; Martin PL; Moffat GJ; Sivaraman L; Tornesi MB; Chivers S
    Birth Defects Res B Dev Reprod Toxicol; 2013 Dec; 98(6):459-85. PubMed ID: 24391099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer.
    Porter C; Armstrong-Fisher S; Kopotsha T; Smith B; Baker T; Kevorkian L; Nesbitt A
    J Reprod Immunol; 2016 Aug; 116():7-12. PubMed ID: 27123565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FcRn Expression on Placenta and Fetal Jejunum during Early, Mid-, and Late Gestation in Minipigs.
    Jacobsen B; Hill M; Reynaud L; Hey A; Barrow P
    Toxicol Pathol; 2016 Apr; 44(3):486-91. PubMed ID: 26516163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfer of antibodies directed to paternal major histocompatibility class I antigens from pregnant mice to the developing fetus.
    Adeniyi-Jones SC; Ozato K
    J Immunol; 1987 Mar; 138(5):1408-15. PubMed ID: 3805722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
    Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
    J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placental transfer of
    Catlin NR; Mitchell AZ; Potchoiba MJ; O'Hara DM; Wang M; Zhang M; Weinbauer GF; Bowman CJ
    Birth Defects Res; 2020 Jan; 112(1):105-117. PubMed ID: 31746560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the neonatal Fc-receptor in placental-fetal endothelium and in cells of the placental immune system.
    Kiskova T; Mytsko Y; Schepelmann M; Helmer H; Fuchs R; Miedl H; Wadsack C; Ellinger I
    Placenta; 2019 Mar; 78():36-43. PubMed ID: 30955709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placental transfer of a fully human IgG2 monoclonal antibody in the cynomolgus monkey, rat, and rabbit: a comparative assessment from during organogenesis to late gestation.
    Moffat GJ; Retter MW; Kwon G; Loomis M; Hock MB; Hall C; Bussiere J; Lewis EM; Chellman GJ
    Birth Defects Res B Dev Reprod Toxicol; 2014 Apr; 101(2):178-88. PubMed ID: 24753333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
    Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
    Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FcRn: the neonatal Fc receptor comes of age.
    Roopenian DC; Akilesh S
    Nat Rev Immunol; 2007 Sep; 7(9):715-25. PubMed ID: 17703228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
    J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No association of FCRN promoter VNTR polymorphism with the rate of maternal-fetal IgG transfer.
    Freiberger T; Ravcuková B; Grodecká L; Kurecová B; Jarkovský J; Bartonková D; Thon V; Litzman J
    J Reprod Immunol; 2010 Jun; 85(2):193-7. PubMed ID: 20452034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice.
    Kliwinski C; Cooper PR; Perkinson R; Mabus JR; Tam SH; Wilkinson TM; Giles-Komar J; Scallon B; Powers GD; Hornby PJ
    Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(3):G262-70. PubMed ID: 23220220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting fetal perchlorate dose and inhibition of iodide kinetics during gestation: a physiologically-based pharmacokinetic analysis of perchlorate and iodide kinetics in the rat.
    Clewell RA; Merrill EA; Yu KO; Mahle DA; Sterner TR; Mattie DR; Robinson PJ; Fisher JW; Gearhart JM
    Toxicol Sci; 2003 Jun; 73(2):235-55. PubMed ID: 12700398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport.
    Leach JL; Sedmak DD; Osborne JM; Rahill B; Lairmore MD; Anderson CL
    J Immunol; 1996 Oct; 157(8):3317-22. PubMed ID: 8871627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.
    Crofts F; Rohatagi S; Pino M; DeLise B; Zhang J; Nguyen M; Guittin P; Barbellion S; Brunel P; Hofmann T; Schmidt J; Wong M; Lockey P; Lerman S; Clark R
    Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):69-79. PubMed ID: 15098200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
    Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
    MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.